Palvella Therapeutics (NASDAQ:PVLA) Now Covered by Analysts at Jones Trading

Jones Trading started coverage on shares of Palvella Therapeutics (NASDAQ:PVLA) in a research report report published on Tuesday,Benzinga reports. The brokerage issued a buy rating and a $45.00 price target on the stock.

Several other equities analysts have also commented on PVLA. Canaccord Genuity Group reaffirmed a “buy” rating and set a $39.00 target price on shares of Palvella Therapeutics in a report on Wednesday, February 26th. Cantor Fitzgerald initiated coverage on Palvella Therapeutics in a research note on Wednesday, December 18th. They set an “overweight” rating for the company. HC Wainwright reiterated a “buy” rating and issued a $38.00 target price on shares of Palvella Therapeutics in a research note on Tuesday, February 11th. TD Cowen began coverage on shares of Palvella Therapeutics in a report on Wednesday, February 5th. They set a “buy” rating and a $44.00 price target for the company. Finally, Scotiabank assumed coverage on shares of Palvella Therapeutics in a report on Friday, March 7th. They issued a “sector outperform” rating and a $50.00 price objective on the stock. Six equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $43.50.

Palvella Therapeutics Price Performance

NASDAQ PVLA opened at $27.76 on Tuesday. The firm has a market cap of $311.49 million, a price-to-earnings ratio of -2.29 and a beta of 0.54. Palvella Therapeutics has a one year low of $6.20 and a one year high of $29.27. The firm has a 50-day simple moving average of $19.95.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. BML Capital Management LLC acquired a new stake in Palvella Therapeutics in the fourth quarter worth about $506,000. Frazier Life Sciences Management L.P. acquired a new position in Palvella Therapeutics during the 4th quarter valued at about $7,847,000. Cresset Asset Management LLC bought a new stake in shares of Palvella Therapeutics during the 4th quarter worth about $251,000. Suvretta Capital Management LLC acquired a new stake in shares of Palvella Therapeutics in the 4th quarter worth approximately $8,574,000. Finally, DAFNA Capital Management LLC bought a new position in shares of Palvella Therapeutics in the fourth quarter valued at approximately $857,000. Institutional investors own 40.11% of the company’s stock.

About Palvella Therapeutics

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.